Get the Stockscreener App
11.92
0.34%
0.04
After Hours:
11.92
Y Mabs Therapeutics Inc stock is traded at $11.92, with a volume of 187.30K.
It is up +0.34% in the last 24 hours and down -19.13% over the past month.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
See More
Previous Close:
$11.88
Open:
$11.88
24h Volume:
187.30K
Relative Volume:
0.74
Market Cap:
$533.89M
Revenue:
$84.82M
Net Income/Loss:
$-21.43M
P/E Ratio:
-13.39
EPS:
-0.89
Net Cash Flow:
$-27.23M
1W Performance:
+14.51%
1M Performance:
-19.13%
6M Performance:
-2.85%
1Y Performance:
+99.66%
1-Day Range:
$11.75
$12.40
1-Week Range:
$10.38
$12.40
52-Week Range:
$6.00
$20.90
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Name
Y Mabs Therapeutics Inc
Sector
Industry
Phone
212-847-9841
Address
230 PARK AVENUE, NEW YORK, NY
Compare YMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
11.92 | 533.89M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | Oppenheimer | Outperform |
| Aug-16-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-28-24 | Initiated | Truist | Buy |
| May-10-23 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-27-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-23 | Downgrade | Cowen | Outperform → Market Perform |
| Dec-02-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-31-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-31-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-03-22 | Resumed | Guggenheim | Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-16-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-07-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-22-21 | Resumed | JP Morgan | Overweight |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| May-01-20 | Initiated | Janney | Buy |
| Apr-29-20 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Initiated | Wedbush | Outperform |
| Apr-01-19 | Initiated | H.C. Wainwright | Buy |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Oct-16-18 | Initiated | BofA/Merrill | Buy |
View All
Y Mabs Therapeutics Inc Stock (YMAB) Latest News
Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference - The Manila Times
Y-mAbs Therapeutics to Present at Citi's 2024 Global Healthcare Conference | YMAB Stock News - StockTitan
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Principal Financial Group Inc. Makes New Investment in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Call Transcript - MSN
Oppenheimer Begins Coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Y-mAbs started at outperform at Oppenheimer on pre-targeted radiotherapies - MSN
Oppenheimer Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Outperform Recommendation - MSN
The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26% - Simply Wall St
Brain Cancer Treatment Market Growth Overview Future - openPR
Y-mAbs Therapeutics (NASDAQ:YMAB) Coverage Initiated by Analysts at Oppenheimer - MarketBeat
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock - Benzinga
Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Receives Buy Rating from HC Wainwright - MarketBeat
Trading (YMAB) With Integrated Risk Controls - Stock Traders Daily
Paradigm Biocapital Advisors LP Bolsters Position in Y-mAbs Ther - GuruFocus.com
YMAB FY2024 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Asia Deal Watch: Apollo Takes A Shine To Chinese Biotech’s Cardiometabolic Candidate - Scrip
Cantor Fitzgerald Issues Positive Outlook for YMAB Earnings - MarketBeat
Investors might be losing patience for Y-mAbs Therapeutics' (NASDAQ:YMAB) increasing losses, as stock sheds 13% over the past week - Simply Wall St
Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR
Y-mAbs Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsY-mAbs Therapeutics, a biopharmaceutical company focusing on innovative radioimmunotherapy and antibody-based products for cancer treatment, rec - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down After Earnings Miss - Defense World
Earnings call: Y-mAbs Therapeutics reports Q3 2024 financials - Investing.com India
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates - MSN
Y-mAbs Therapeutics (NASDAQ:YMAB) Issues Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada
Y-mAbs Therapeutics Inc (YMAB) Quarterly 10-Q Report - Quartzy
Y-mAbs Reports Third Quarter 2024 Financial Results - TipRanks
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap DownShould You Sell? - MarketBeat
Y-mAbs Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2024 - Marketscreener.com
Y mAbs Therapeutics earnings missed by $0.01, revenue fell short of estimates - Investing.com Canada
Y-mAbs Therapeutics Inc Reports Q3 2024 Revenue of $18.5 Million - GuruFocus.com
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments - The Manila Times
Y-mAbs Q3 Revenue Falls 10%, But Secures Key Japan Deal and Patent Extension | YMAB Stock News - StockTitan
Examining the Future: Y-mAbs Therapeutics's Earnings Outlook - Benzinga
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earni - GuruFocus.com
Exclusive License Agreement Between Y-mAbs Therapeutics, Inc. and Nobelpharma Co., Ltd. for Development and Commercialization of DANYELZA(R) in Japan - Defense World
(YMAB) Trading Advice - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Y-mAbs Therapeutics Inc - GuruFocus.com
Y-mAbs enters Japan market with Nobelpharma for cancer therapy By Investing.com - Investing.com Canada
Y-mAbs enters Japan market with Nobelpharma for cancer therapy - Investing.com
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan - The Manila Times
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates - MSN
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know - MSN
Y-mAbs Therapeutics (YMAB) Scheduled to Post Earnings on Friday - MarketBeat
Y-mAbs Therapeutics (YMAB) Scheduled to Post Quarterly Earnings on Friday - Defense World
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Benzinga
Y Mabs Therapeutics Inc Stock (YMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):